CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$1.97 USD
-0.01 (-0.51%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $1.97 0.00 (0.00%) 5:56 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 81 - 100 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Namodenoson Top-line Phase 2 Results in NASH Now Expected in April; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Namodenoson Top-line Phase 2 Results in NASH Expected This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Updates the Timelines, Steady Progress with Namodenoson in Liver Cancer, NASH - More
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Compassionate Use Begins In Advance of Pivotal Program
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
FDA Agrees That Can-Fite''s Proposed Pivotal Namodenoson Phase 3 Could Support an NDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
The FDA Gives Can-Fite a Treat Go Pivotal in HCC
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Phase 2 Proof of Concept in NAFLD- Enrolled
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Maintain Buy With a PT Adjusted From $30 to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Compassionate Use in Israel - A Deal in Korea
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Expecting Pipeline Progress to Generate Positive Catalysts Through 2019; Reiterate Buy With PT Adjusted to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V